Spinal Muscular Atrophy: Therapeutic Strategies

Current Treatment Options in Neurology

Volumn 16, Issue 11, 2014, Pages

  Castro, Diana ^a   Iannaccone, Susan T ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti sense oligonucleotides; Floppy baby; SMA; Spinal muscular atrophy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLESOXIME; QUINAZOLINE DERIVATIVE; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; VIRUS VECTOR;

ALPHA NERVE FIBER; BODY MASS; CHILD NUTRITION; DEATH; DIETARY INTAKE; DIETITIAN; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXON; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GENETICS; GROWTH DISORDER; HUMAN; LUNG DISEASE; MEDICAL SPECIALIST; MOUSE MODEL; MUSCLE FUNCTION; NEUROPROTECTION; NONHUMAN; NUTRITIONAL HEALTH; OBESITY; ORTHOPEDICS; PALLIATIVE THERAPY; PARALYSIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT REFERRAL; PREMATURE DEATH; PROGRESSIVE PARALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; REHABILITATION; RESPIRATORY CARE; REVIEW; RNA TRANSCRIPTION; SPINAL CORD; SPINAL CORD VENTRAL HORN; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; SURVIVAL; WEIGHT GAIN;

EID: 84920191473     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0316-3     Document Type: Review

References (19)

1. Werdnig G. Zwei frühinfantile hereditäre Fälle von progressive Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage [Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis; in German]. Arch Psychiatr Nervenkr. 1891;22:437–80.
2. Hoffmann J. U” ber chronische spinale Muskelatrophie im Kindesalter, auf familiärer Basis [On chronic spinal muscular atrophy in childhood, with a familial basis; in German]. Dtsch Z Nervenheilkd. 1893;3:427–70.
3. Byers RK, Banker BQ. Infantile muscular atrophy: en eleven-year experience. Trans Am Neurol Assoc. 1960;85:10–4.
4. Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110:301–7.
5. Zaldivar T, Montejo Y, Acevedo AM, Guerra R, Vargas J, Garofalo N, et al. Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. Neurology. 2005;65:636–8.
6. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. J Child Neurol. 2007;22:1027.
7. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443–52. A brief communication bringing the reader up to date for standard of care for children with SMA. The authors who are well known for their expertise in the care of SMA patients include a discussion of new and emerging therapies in pre-clinical or clnical testing.
8. Willig TN, Paulus J, Lacau-Saint-Guily J, et al. Swallowing problems in neuromuscular disorders. Arch Phys Med Rehabil. 1994;75:1175–81.
9. Tilton AH, Miller MD, Khoshoo V. Nutrition and swallowing in pediatric neuromuscular patients. Semin Pediatr Neurol. 1998;5:106–15.
10. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–57.
11. Jones M, Campbell KA, Duggan C, et al. Multiple micronutrient deficiencies in a child fed an elemental formula. J Pediatr Gastroenterol Nutr. 2001;33:602–5.
12. Van den Engel-Hoek L, Erasmus C. Dysphagia in spinal muscular atrophy type II. Neurology. 2009;73:1787–91.
13. Messina S, Pane M, et al. Feeding problems and malnutrition in spinal muscular atrophy type I. Neuromuscul Disord. 2008;18:389–93.
14. Chng S, Wong Y, Hui J, et al. Pulmonary function and scoliosis in children with spinal muscular atrophy types II and III. J Paediatr Child Health. 2003;39:673–6.
15. Zanetta C, Riboldi G, Nizzardo M, Simone C, Faravelli I, Bresolin N, et al. Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA). J Cell Mol Med. 2014;18:187–96. This is an in depth review of new therapeutic strategies for childhood SMA. The authors are prominent Italian clinician scientists and they provide and excellent summary of the mechanism of action for each of the approaches with many references.
16. Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clin Ther. 2014;36:128–40. These authors are the same as for #15, but this article presents an up to date summary of actual clinical trials either recently completed or still in process for SMA. there is description of mechanism of action for the investigational product as well as summary of the protocol for each study.
17. Yee J-K, Lin R-J. Antisense Oligonucleotides Shed new light on the pathogenesis and treatment of Spinal Muscular Atrophy. Mol Ther. 2012;20:8–10.
18. Braun S. Gene-based therapies of neuromuscular disorders: an update and the pivotal role of patient organizations in their discovery and implementation. J Gene Med. 2013;15:397–413. This is an interesting review/comment on the role that patient/volunteer disease-specific organizations have played in drug development for neuromuscular disorders. Such organizations have become increasingly important for the field in the past 15 years. Changes in the way clinical research is done for neuromuscular patients have been historic, very much like the influence the AIDS community had on clinical drug development in the 1980s.
19. Singh P, Liew WKM, Darras BT. Current advances in drug development in spinal muscular atrophy. Curr Opin Pediatr. 2013;25:682–8.